ENTITY
FDA Requests Flu Vaccine Label Updates for Febrile Seizure Risk in Young Children
FDA; flu vaccine; febrile seizures; label update; children; influenza vaccine
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease
Sentynl Therapeutics; ZYCUBO; FDA approval; Menkes disease; copper histidinate; Zydus Lifesciences
JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates
JPM26; GSK; J.P. Morgan Healthcare Conference; Day 2; AstraZeneca; Novo Nordisk; biotech
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos
JPM26 Day 1 Live Blog: Slow Deal Flow Amid Optimism at J.P. Morgan Healthcare Conference
JPM26; J.P. Morgan Healthcare Conference; deal flow; AI healthcare; biotech; M&A
FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]
FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02
FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026
FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary
Eli Lilly and Nvidia Announce $1 Billion, Five-Year AI Co-Innovation Lab Partnership in Bay Area
Eli Lilly; Nvidia; AI lab; drug discovery; $1 billion; Bay Area; JPM 2026